{"id":402761,"date":"2025-11-25T03:51:33","date_gmt":"2025-11-25T03:51:33","guid":{"rendered":"https:\/\/www.europesays.com\/us\/402761\/"},"modified":"2025-11-25T03:51:33","modified_gmt":"2025-11-25T03:51:33","slug":"denmark-compensates-four-over-vision-loss-linked-to-ozempic-wegovy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/402761\/","title":{"rendered":"Denmark compensates four over vision loss linked to Ozempic, Wegovy"},"content":{"rendered":"

\"The<\/p>\n

\nMore than 40 people in Denmark have sought reimbursement after they said they had developed a serious eye condition as a result of using Ozempic or Wegovy.
\nPhoto: Ida Marie Odgaard \/ Ritzau Scanpix via AFP\n<\/p>\n

Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs<\/a> Wegovy and Ozempic are entitled to compensation, an independent body has ruled.<\/p>\n

More than 40 people had sought reimbursement after they said they had developed a serious eye condition as a result of using one of the drugs, both made by Novo Nordisk, according to the Danish Patient Compensation association.<\/p>\n

The condition — NAION (non-arteritic anterior ischemic optic neuropathy) — is a lack of blood supply to the optic nerve, which can lead to a loss of vision.<\/p>\n

The association said that it had ruled on five cases so far, and found four people who merited compensation.<\/p>\n

“It’s unfortunate for the patients who have been affected by the side effect. NAION is a serious condition that causes permanent and incurable damage to vision,” the association’s director, Karen-Inger Bast, said in a statement.<\/p>\n

Bast added that the cases were difficult to assess given that it was new medicine and the patients were already at increased risk of developing NAION.<\/p>\n

In total, the four patients would receive 800,000 kroner (NZ$220,456), but the association noted that the amount could increase depending on the impact the condition could have on their lives going forward — for instance, if it affects their ability to work.<\/p>\n

Medical compensation in Denmark is generally paid out by health authorities<\/a>.<\/p>\n

Last year, the Danish Medicines Agency asked a European medical watchdog to review a Danish study that showed a link between semaglutide — the active ingredient in Ozempic and Wegovy — and NAION.<\/p>\n

In June, that watchdog — the PRAC (Pharmacovigilance Risk Assessment Committee) — concluded that NAION was a “very rare” side effect of semaglutide, affecting up to 1 in 10,000 users.<\/p>\n

Novo Nordisk said it had reviewed the decision by the Danish Patient Compensation.<\/p>\n

In a statement sent to AFP, the drugmaker noted that following PRAC’s findings, patient leaflets for all semaglutide products had been updated to include NAION as a “very rare” reaction to the drugs.<\/p>\n

But it said the “benefit-risk profile of semaglutide remains favorable”.<\/p>\n

– AFP<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"More than 40 people in Denmark have sought reimbursement after they said they had developed a serious eye…\n","protected":false},"author":3,"featured_media":402762,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[5157,3240,210,1060,50,5158,5156,5154,5155,67,132,68],"class_list":{"0":"post-402761","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-audio","9":"tag-current-affairs","10":"tag-health","11":"tag-medication","12":"tag-news","13":"tag-podcasts","14":"tag-public-radio","15":"tag-radio-new-zealand","16":"tag-rnz","17":"tag-united-states","18":"tag-unitedstates","19":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115608308501214910","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/402761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=402761"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/402761\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/402762"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=402761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=402761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=402761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}